Contributors: Universidad de Salamanca; Institute of Health Carlos III; Università degli Studi di Roma "La Sapienza" = Sapienza University Rome (UNIROMA); University of Edinburgh (Edin.); Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA); Università di studi di Padova - Dipartimento di studi linguistici e letterari (UP DISLL); Università degli Studi di Padova = University of Padua (Unipd); Oncogenesis, Stress, Signaling (OSS); Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC); UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM); CRLCC Eugène Marquis (CRLCC); UNICANCER; University of Glasgow; University of Surrey (UNIS); University College of London London (UCL); Universitätsklinikum RWTH Aachen - University Hospital Aachen Aachen, Germany (UKA); Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH); The Christie NHS Foundation Trust Manchester, Royaume-Uni; San Raffaele Scientific Institute; Vita-Salute San Raffaele University and Center for Translational Genomics and Bioinformatics; University of Barcelona; University of the Basque Country = Euskal Herriko Unibertsitatea (UPV / EHU); Università degli studi di Roma “Foro Italico” Italia = Foro Italico University of Rome Italy Istituto Universitario di Scienze Motorie (UIMS) = University Institute of Motor Sciences; Christie Charity; European Union's Horizon 2020 Research and Innovation Programme 825510; Instituto de Salud Carlos III PI13/01229, PI18/00542; National Institute for Health Research University College London Hospitals Biomedical Research Centre; FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion grant, Spain PID2019-104878RB-100; AMMF The Cholangiocarcinoma Charity, UK 2018/117; Gobierno de Navarra Salud, Spain 58/2017, 0011-1411-2020-000010; Instituto de Salud Carlos III, Spain (European Regional Development Fund/European Social Fund, 'Investing in your future') PI20/00189; Sapienza University; COST (European Cooperation in Science and Technology) CA18122
نبذة مختصرة : International audience ; Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a consequent poor prognosis. Therefore, the identification of biomarkers represents an utmost need for patients with CCA. Numerous studies proposed a wide spectrum of biomarkers at tissue and molecular levels. With the present paper, a multidisciplinary group of experts within the European Network for the Study of Cholangiocarcinoma discusses the clinical role of tissue biomarkers and provides a selection based on their current relevance and potential applications in the framework of CCA. Recent advances are proposed by dividing biomarkers based on their potential role in diagnosis, prognosis and therapy response. Limitations of current biomarkers are also identified, together with specific promising areas (ie, artificial intelligence, patient-derived organoids, targeted therapy) where research should be focused to develop future biomarkers.
Processing Request
No Comments.